The Best Targets for Biogenerics - - BioPharm International


The Best Targets for Biogenerics

BioPharm International
Volume 19, Issue 4


Financial Inclusion Criteria

For a branded protein pharmaceutical product to have any value to a potential biogeneric manufacturer, it must have an adequate potential for economic return to justify the significant investment required to develop the biogeneric mimic. We arbitrarily selected $20 million as the minimum annual product sales for any branded product to justify developing even the simplest of biogeneric mimics. This figure errs, if anything, on the side of including some products that may not be economically feasible targets, but it was decided that providing a comprehensive list was of greater value than providing an incomplete, but highly selective list.

The starting data set for this analysis, therefore, consisted of a list of all pharmaceutical products (including protein and small-molecule products) for which the 12 full months' worth of US sales data from September 2004 to August 2005 was at least $20 million.11 From this preliminary list, all protein and peptide products were identified and retained, while all small molecule products were removed from consideration.

Exclusion Criteria

Table 1. Classes of products excluded from consideration
Once the list of all protein and peptide products with annual sales of at least $20 million was prepared, products that fell into the categories listed in Table 1 were removed. The specific reasons for removing each category from consideration are provided in the table, but the more general rationale is that these types of products have not been part of the mainstream discussions of biogenerics. These excluded products represent either classical biological products that clearly fit within the literal PHSA definition of "biological products" and have remained under the jurisdiction of CBER, or highly specialized situations not amenable to generalized regulatory guidance. Excluding such products from this analysis is not meant to suggest that they cannot be genericized, but simply highlights the fact that they have not been considered in the recent discussions of biogeneric products.

Recent Public Discussion
The products remaining on the list at this point were consistent with the focus of recent public discussions, which have been about developing biogenerics for well-characterized (or at least well-characterizable) recombinant DNA and natural source target products. (For more on the discussions see the sidebar.)

Data Consolidation

The final adjustment to the list of biogeneric targets was to group redundant entries together as if they were single products. The first criterion used for this grouping was to consolidate entries for products that were deemed therapeutically equivalent (A-rated) in FDA's Orange Book.12 The second criterion was to consolidate all products from a single manufacturer containing the same active ingredient; the rationale was that the same active ingredient from the same manufacturer, though used in different finished products, ought to be the same.

The result of these consolidations, therefore, was a list in which each entry contains a unique active ingredient. This approach was taken in part to avoid undue weighting of some products, particularly insulins, for which several distinct formulations are available from a given manufacturer using a single active ingredient.

Product Attributes Each product on the final list of biogeneric target products was examined for a variety of characteristics, including filing mechanism (NDA or BLA), number of amino acid residues, major chemical modification (glycosylation, PEGylation), source (synthetic, rDNA, or native DNA), expression system (where appropriate), and whether the product bears a current A-rating (indicating therapeutic equivalence) in FDA's Orange Book.

Table 2a. Biogeneric target products with annual US sales > $20 million
Most of this information was derived from package inserts for the products, although some was obtained from other sources, such as publicly disclosed product approval or licensing information available through FDA's Freedom of Information Act (FOI) Office, and scientific publications.

blog comments powered by Disqus



Lundbeck CEO Resigns Due to Code of Conduct Breach
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Janssen Partners with Transposagen Biopharmaceuticals for CAR-T Therapies
November 24, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here